Enzo Biochem (ENZ)
(Real Time Quote from BATS)
$1.12 USD
-0.02 (-1.75%)
Updated Sep 20, 2024 03:42 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Enzo Biochem, Inc falls in the month of July.
All items in Millions except Per Share data.
7/31/2024 | 7/31/2023 | 7/31/2022 | 7/31/2021 | 7/31/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 82 | 22 | 44 | 48 |
Receivables | NA | 5 | 12 | 10 | 9 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 8 | 15 | 13 | 8 |
Other Current Assets | NA | 3 | 6 | 4 | 4 |
Total Current Assets | NA | 98 | 54 | 71 | 69 |
Net Property & Equipment | NA | 13 | 17 | 17 | 14 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 1 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 7 | 8 | 8 |
Deposits & Other Assets | NA | 6 | 2 | 2 | 1 |
Total Assets | NA | 122 | 96 | 114 | 113 |
Liabilities & Shareholders Equity | 7/31/2024 | 7/31/2023 | 7/31/2022 | 7/31/2021 | 7/31/2020 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 4 | 9 | 8 | 9 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 7 |
Current Portion Capital Leases | NA | 3 | 0 | 0 | 0 |
Accrued Expenses | NA | 12 | 12 | 14 | 13 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 21 | 0 | 0 | 0 |
Total Current Liabilities | NA | 40 | 25 | 26 | 33 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 4 | 4 | 4 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 43 | 41 | 45 | 54 |
Shareholders Equity | 7/31/2024 | 7/31/2023 | 7/31/2022 | 7/31/2021 | 7/31/2020 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 1 | 0 | 0 | 0 |
Capital Surplus | NA | 344 | 339 | 337 | 334 |
Retained Earnings | NA | -268 | -289 | -270 | -278 |
Other Equity | NA | 2 | 3 | 1 | 2 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 78 | 54 | 69 | 58 |
Total Liabilities & Shareholder's Equity | NA | 122 | 96 | 114 | 113 |
Total Common Equity | 0 | 78 | 54 | 69 | 58 |
Shares Outstanding | 51.40 | 49.60 | 48.70 | 48.40 | 47.80 |
Book Value Per Share | 0.00 | 1.58 | 1.12 | 1.42 | 1.22 |
Fiscal Year End for Enzo Biochem, Inc falls in the month of July.
All items in Millions except Per Share data.
7/31/2024 | 4/30/2024 | 1/31/2024 | 10/31/2023 | 7/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 57 | 60 | 69 | 82 |
Receivables | NA | 4 | 5 | 4 | 5 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 7 | 8 | 8 | 8 |
Other Current Assets | NA | 7 | 8 | 7 | 3 |
Total Current Assets | NA | 76 | 81 | 88 | 98 |
Net Property & Equipment | NA | 13 | 13 | 13 | 13 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 2 | 1 | 1 | 1 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 1 | 1 | 1 | 6 |
Total Assets | NA | 93 | 99 | 106 | 122 |
Liabilities & Shareholders Equity | 7/31/2024 | 4/30/2024 | 1/31/2024 | 10/31/2023 | 7/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 1 | 2 | 4 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 4 | 3 | 3 | 3 |
Accrued Expenses | NA | 5 | 8 | 10 | 12 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 10 | 12 | 13 | 21 |
Total Current Liabilities | NA | 22 | 25 | 29 | 40 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 24 | 28 | 32 | 43 |
Shareholders Equity | 7/31/2024 | 4/30/2024 | 1/31/2024 | 10/31/2023 | 7/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 1 | 1 | 1 | 1 |
Capital Surplus | NA | 347 | 346 | 346 | 344 |
Retained Earnings | NA | -281 | -278 | -275 | -268 |
Other Equity | NA | 3 | 2 | 3 | 2 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 69 | 71 | 74 | 78 |
Total Liabilities & Shareholder's Equity | NA | 93 | 99 | 106 | 122 |
Total Common Equity | 0 | 69 | 71 | 74 | 78 |
Shares Outstanding | 51.40 | 51.20 | 50.40 | 50.40 | 49.60 |
Book Value Per Share | 0.00 | 1.35 | 1.40 | 1.47 | 1.58 |